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Abstract
Background: Medication errors represent a noteworthy source of harm to patients. In recent years, several systematic
reviews have assessed the frequency and causes of these events, as well as other factors such as commonly associated
drugs, their incidence in different specialties, and their consequences to patients. Despite this past literature,
there remains a need to study discrepancies between these reviews and establish the current state of the
evidence. The planned review will bring together, compare, and contract existing evidence related to the
occurrence of medication errors in acute and continuing/long-term care settings.
Methods: A systematic review of reviews will be performed. A literature search designed by an experienced
information specialist will be carried out in Medline, Embase, and the Cochrane Library. We will seek systematic reviews
and meta-analyses of primary research studies that evaluate one or more of the following aspects of the occurrence of
preventable adverse drug events in hospitals and long-term care centers: the incidence of preventable adverse drug
events, either overall or within subgroups of interest related to setting; drug or patient characteristics; cited consequences
of these events to patients, including death, emergency room visits, or other outcomes; and established causes of the
preventable adverse drug events. Two researchers will independently screen all abstracts and full texts for study selection
and subsequently perform data extraction from all included studies. Quality of the reviews will be assessed using the
assessing the methodological quality of systematic reviews (AMSTAR) tool. Where objectives from two or more reviews
overlap, we will employ the Jadad framework to assess the causes of any noted discrepancies between
reviews. An overall summary of results will be performed using tabular and graphical approaches and will
be supplemented by narrative description.
Discussion: This overview will help synthesize the broad degree of information available on this important
topic. This review is being performed by members of the Drug Safety and Effectiveness Network along with
collaboration from Health Canada, and its findings will be published in a peer-reviewed journal. The results
may also inform future research in this area.
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Background
Medical errors are the third leading cause of death in
the USA, only behind heart disease and cancer [1]. The
2004 Canadian Adverse Events Study reported an inci-
dence of 70,000 preventable adverse events per 2.5 million
annual hospitalizations in Canada. Investigators estimated
that between 9250 and 23,750 deaths due to adverse
events could have been prevented in the year 2000 alone
[2]. Although the Canadian Adverse Events Study identi-
fied that 24% of adverse events were due to medications
[2], the study was not designed to capture medication
errors specifically; these are often not well documented
and can be difficult to detect. For example, errors due to
inappropriate use or inadequate monitoring likely would
not have been captured [3].
These types of pivotal studies highlight an opportunity to
improve care provided to patients while additionally redu-
cing the burden on our healthcare system. Development of
an enhanced understanding of why, how, when, and where
preventable adverse events occur could inform potential in-
terventions to reduce the risk of their occurrence. Because
medications are involved in almost a quarter of all adverse
events, this represents a logical first target in addressing this
issue. Preliminary scoping of the literature in this area sug-
gests that there exist a number of review articles that have
sought to characterize the prevalence of adverse drug
events in different populations and settings [4–11]. Some of
the previous research incorporated estimation of the pro-
portion of preventable adverse drug events. However, an
assessment of research methods and discussions among
academic researchers highlighted the existence of confusion
regarding terminology such as adverse drug events, adverse
drug reactions, medication errors, and medication incidents
[12]. Variations in endpoint definitions and preventability
criteria are likely to be associated with differences in
findings across published studies.
The Institute for Safe Medication Practices (ISMP)
Canada defines an adverse drug event as “An injury from a
medicine or lack of an intended medicine” and “includes
adverse drug reactions and harm from medication incidents
[13].” An adverse drug reaction is defined by the World
Health Organization as “any response to a drug which is
noxious and unintended which occurs at doses normally
used in man for prophylaxis, diagnosis, or therapy of dis-
ease, or for the modifications of physiological function [14]”
and is a type of adverse drug event by these definitions. The
occurrence of a preventable adverse drug event implies that
an injury or harm occurred as a result of a medication
error, which is further defined as “a failure in the treatment
process that leads to, or has the potential to lead to, harm
to the patient [15].” In contrast, ISMP refers to this as a
“medication incident [13].”
Currently, Health Canada’s guidance with respect to
adverse reaction reporting indicates that all suspected
adverse drug reactions should be reported, especially if
they are associated with drugs newly marketed within
the past 5 years, are unexpected, or are serious [16]. Ad-
verse reactions are defined broadly by Health Canada as
a “noxious and unintended effect to health products
[16].” The passing of “Vanessa’s law” in 2014 will require
that all serious adverse drug reactions are reported by
healthcare institutions; however, the accompanying regu-
lations are still in development.
In theory, mandatory reporting of serious adverse drug
reactions by all health care practitioners could be an im-
portant step in improving post-market surveillance. How-
ever, mandatory reporting would represent a major change
in practice, increased workload for health professionals, and
potential increased cost to the health care system. Report-
ing rates have been shown to be low even in countries such
as New Zealand where there has been “mandatory” report-
ing of adverse drug reactions by health professionals. Thus,
enforcing such a requirement would be challenging [17].
Our research team is interested in further developing an
understanding of the magnitude of preventable adverse
drug events within the broader context of pharmacovigi-
lance, with the notion that such knowledge may prove
useful to inform modifications of current post-market sur-
veillance activities. Preliminary searching of the literature
suggests there are a variety of existing systematic reviews
that study the incidence of preventable adverse drug events.
In such situations, an overview of reviews [18, 19] is a
logical study design, affording the research team the oppor-
tunity for (a) comparison of review findings to establish
their degree of consistency or differences when their
objectives overlap, as well as assessment of differ-
ences in methods (e.g., inclusion criteria, analytic
plan, or other aspects of study rigor), included stud-
ies, outcomes assessed, and other factors which may
be associated with any observed differences in find-
ings; (b) compilation of complementary but distinct
information from different reviews to be brought into
one source; and (c) identification of gaps in terms of
outcomes of importance not yet studied or important
variations across reviews in those that have been
studied.
An overview of reviews (i.e., a systematic review of
systematic reviews) will enable us to map and compare
the objectives, methods, and findings of existing system-
atic reviews related to this topic to develop a greater
understanding of the information available regarding the
incidence of preventable adverse drug events, common
factors contributing to preventable adverse drug events,
and other considerations. These reviews may have rele-
vant/related but different objectives and include a variety
of study types and variations in study methods and
characteristics which can provide data related to the
objectives of the review.
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Study methods
This protocol describes the methods to be followed
for conduct of the planned overview of reviews.
Methods have been chosen in consultation with the
Cochrane Handbook’s chapter on methods for over-
views of reviews [18], as well as recent work by
Smith [19]. As the objective of the review will be to
compare and contrast findings regarding measures of
preventable adverse drug events across reviews,
Jadad’s framework for assessment of discordant reviews
will also be used [20]. This review has been registered in
the PROSPERO database (CRD42016043220), and this
protocol has been prepared in consultation with the
PRISMA-P statement [21, 22] (checklist provided in the
supplemental documents to this protocol, in Additional
file 1). Any amendments to the protocol shall be described
in the final review.
Research questions to be addressed
This study has been designed to answer the following pri-
mary research question: What is the incidence of prevent-
able adverse drug events in acute and continuing/long-
term care hospitals/institutions (including both academic
and community hospitals)? In the context of the review, a
series of secondary objectives will also be addressed. These
will include assessment of PADR incidence within differ-
ent patient age groups (e.g., pediatric, adult, and elderly
patients), settings (e.g., acute, continuing, and long-term
care; academic vs community hospitals), and clinical spe-
cialties (e.g., emergency medicine, cardiology); assessment
of the different cited types and causes of preventable
adverse drug events (both with their corresponding distri-
bution of frequency); and the severity of patient outcomes
associated with their occurrence.
Study eligibility criteria




Studies involving patients receiving acute or ambula-
tory care from hospitals and being treated with drug
therapy will be sought. Studies in other institutional
settings such as long-term care facilities will also be
included. Studies related to primary care will not be
eligible. However, data coming from inpatient vs out-
patient settings as well as hospital-based vs other set-
tings will be eligible.
Intervention/comparators
No specific intervention is required for a study to be eli-
gible for this overview of reviews; studies reporting eligible
patient data and patient outcomes will be included. Studies
with some aspect of causality between a drug and an event
are of primary interest though those studies without a
clear causal association are also of interest.
Outcomes
A specific definition for preventable adverse drug event
will not be established as an a priori eligibility criteria.
Definitions are likely to vary by study and may be highly
associated with variations in results. As such, studies
with variable definitions will be included, and any dis-
crepancies in results associated with different definitions
will be formally assessed. Reviews that include studies
dealing with ameliorable adverse drug events (i.e., those
that could not have been prevented but whose severity
could have been limited) or studies related to interac-
tions with herbal or non-prescription medications will
be included. Those reporting on the occurrence of
adverse drug events where medications were adequately
administered will not be eligible. With regard to mea-
sures of interest for the current review, studies will be
included if they have addressed one or more measures
among incidence of preventable adverse drug events,
distribution of causes observed (including miscommuni-
cated drug orders, drug packaging/labeling problems,
drug storage and delivery problems, lack of staff or
patient education, lack of quality check mechanism, and
other forms of cause), patient consequences (including no
harms incurred, hospitalization incidence, requirement for
life-saving interventions, emergency room visit, death,
quality of life changes, and other consequences), and eval-
uations of severity. Incidence of preventable adverse drug
events will be the primary outcome of interest, while
all others will be considered secondary outcomes.
Study design
The current study is designed to be an overview of
existing reviews, and thus, eligible study designs will
be restricted to those which have employed a systematic
review design. We will consider publications to be system-
atic reviews if they were clearly described in the report as
being based on a systematic search of one or more elec-
tronic literature databases, clearly specified the review
question and eligibility criteria, involved study selection
and data collection by two or more reviewers, performed
some form of risk of bias appraisal of included studies,
and synthesized all information using a quantitative or
qualitative approach. Review articles not meeting these
criteria will be excluded.
Searching the literature for relevant studies
A search strategy has been established with the participa-
tion of an experienced information specialist (BS) and
independently peer-reviewed by a second information spe-
cialist using PRESS criteria (Additional file 2) [23]. We will
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search Medline, Embase, and the Cochrane Library with-
out date restrictions. Key search terms will include
the following: adverse drug reaction reporting systems,
drug-related side effects and adverse reactions, medi-
cation errors, and an in-depth list of text words given
the nature of varying terminology in this area. The
search will be restricted to publications in English
and French.
Process of study selection
Two reviewers will independently screen all citations
identified from the literature search described above.
All citations judged potentially eligible will be screened
in full text; any disagreements will be settled by con-
sultation of a third member of the review team. An
analogous process will be used to screen full texts.
Both stages of screening will be preceded by a piloting
exercise to ensure that reviewers have a similar under-
standing of the eligibility criteria. As recommended by
the PRISMA Statement [24], a flow diagram will be
presented to describe the process of study selection.
Management of all screening will be performed using
the Distiller SR software (Evidence Partners Inc.,
Ottawa, Canada).
Data extraction and risk of bias assessment
Given that we will seek to address multiple objectives,
a broad range of information will be collected from
each of the included studies to derive all relevant
data. This will include each of the following items
described in Table 1; it should be noted that for
many of these items, subsequent synthesis of findings
will involve summarizing/contrasting these features in
relation to the primary studies that each review
assessed. Data collection will be performed by two
reviewers independently, with involvement of a third
reviewer as needed to establish consensus in the pres-
ence of disagreements. A data collection form will be
drafted and piloted on a small number of studies and
discussed among the team to incorporate any neces-
sary refinements prior to completion of data collec-
tion from all relevant studies. Methodological quality/
risk of bias for included systematic reviews will be
performed using the AMSTAR tool [25]; this tool will
help to distinguish the rigor of included reviews in
terms of methods used for literature searching, pro-
cesses for study selection and data collection, data
analysis, and other vital aspects of systematic review
design. A table will be presented displaying the scor-
ing of AMSTAR item assessments for each included
review, which will enable comparison of the rigor and
reporting of included reviews.
All data collection will be performed electronically using
the Microsoft Excel software (Microsoft Corporation,
Seattle, USA).
Synthesis of data
To summarize findings, a descriptive approach will be
taken that will include tables to characterize key features,
findings, and variations of the research, supplemented
with graphics to highlight diversity in study results and
other aspects; guidance from the Cochrane Handbook for
overviews of reviews will be followed. This will also
include a focused effort to map gaps between reviews in
relation to many aspects of preventable adverse drug
events described. The Jadad framework for discordant re-
views will also be used to assess variations in reviews [20].
For reviews addressing the same objectives and endpoints,
their findings will be compared.
In exploring the rationale for variations in findings be-
tween the reviews, several strategies will be employed.
Firstly, comparison of review methods will be performed in
relation to eligibility criteria (i.e., assessment of variations in
criteria used to identify eligible patients, study designs, and
endpoints of interest), literature search details (dates, data-
bases, and key differences in strategies employed; language
restrictions employed), endpoint definitions used, statistical
approaches to meta-analysis (if performed), and rigor of
review methods (as reflected by variations in AMSTAR
assessments and other aspects of study methodology).
Secondly, the evidence base included in different reviews
will be evaluated in terms of their degree of overlap; this
will involve comparison of date ranges of studies covered
by the review, the numbers of studies and patients across
reviews and development of a citation matrix to establish
the similarity of included study lists. Lastly, compari-
son of review findings (e.g., meta-analytic findings
regarding pooled incidence rates or other related mea-
sures) and conclusions drawn by review teams will
also be performed.
Reporting of review findings
To present findings from our review, we will draft a
summary manuscript for publication in a peer-reviewed,
open-access journal. We will follow recommendations
from the PRISMA Statement to guide the reporting of
this work [24], and will include a PRISMA Checklist to
document completeness of reporting.
Discussion
Adverse events related to drugs have been established as
having notable associations with the occurrence of mor-
bidity in patients. Numerous past reviews have addressed
different aspects of questions surrounding the incidence,
causes, and consequences of preventable adverse drug
events. There is a need to map the findings from these
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reviews to enhance our understanding of all the data
currently available, as well as to identify discrepancies in
findings and resolve their sources. These are all intended
goals for the planned overview of reviews. Achieving these
objectives will prove helpful in establishing improved
efforts to reduce the frequency of adverse drug events,
both overall and in terms of the occurrence of events with
particularly severe consequences for patients.
Table 1 Elements for data collection
Aspect of data collection Description of key items to be extracted
General review characteristics and patient traits Primary details gathered will include
• Stated review objectives
• Numbers of included studies and patients
• Date ranges of literature searches
• Study eligibility criteria
• Patients’ age distribution (pediatric vs adult vs elderly)
• Diagnoses/comorbidities of patients studied (number
and/or cluster of comorbid condition)
• Any other key patient/population information that were
noted in the review
Hospital/setting characteristics of each review’s
included studies
Key setting-related factors for each review’s included
studies. Such details will include
• Hospital size characterized by the number of beds
and/or the number of staff
• Academic vs community centers
• Clinical disciplines involved in the primary studies
• Geographic locations of the primary studies
• Any other relevant features presented in each review
regarding its primary studies
Quantitative measures of incidence of preventable
adverse drug events
Outcome data collected will include
• Stated eligible measures/definitions of the endpoints
assessed in each eligible review, including preventable
adverse drugs events and other endpoints related to the
current review objectives
• Corresponding incidence rates of primary studies in each
review’s included studies (and any presented meta-analysis
results thereof, both overall or within specific subgroups of patients)
• Severity assessments as presented for each review’s set of
included studies (if reported)
• Causality or likelihood assessments as presented for each review’s
set of included studies (if reported)
• Method of collection of adverse event data (i.e., spontaneous vs
active surveillance) for each review’s set of included studies (if reported)
Causes of preventable adverse drug events
identified among each review’s included studies
Causes of interest will include (but not be limited to) the following
• Miscommunications of drug order
• Drug name, label, or packaging problem
• Drug storage or delivery problem
• Environmental, staffing, or workflow problem
• Staff or patient education problem
• Lack of quality control or independent check systems
• Problem with electronic data management system
Consequences of adverse drug events Consequences of interest will include (but not be limited to) proportions
of preventable adverse drug events with the following consequences
• No harm done
• Prolonged hospitalization needed
• Life-saving treatment needed
• Hospital readmission
• Emergency department visit readmission
• Transient impact
• Permanent impact
• Quality of life
• Death
• Other outcomes reported
Incidence and types of preventable adverse drug
events reported within key subgroups of interest
Subgroups of interest include (but are not limited to)
• Clinical specialty (cardiology, oncology, etc.)
• Patient age (e.g., pediatric, adults, elderly)
• Presence of comorbidities
• Healthcare setting
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We anticipate certain challenges during the conduct of
the review. These may include variation across reviews in
definitions of preventability (e.g., “inappropriate use” vs
obvious error of omission); methods of measurement of
preventability; definitions of adverse drug event, adverse
drug reaction, medication error, and corresponding varia-
tions in methods for measurement; approaches used to
assess the likelihood of causality; jurisdictional differences
in the reporting of adverse drug events; and settings, popu-
lations, or population characteristics (i.e., inpatient service/
area, type of hospital, age, comorbidities, complexity, num-
ber of medications, etc.). Using rigorous data collection and
a systematic approach to evaluation of endpoints in relation
to study characteristics, we will carefully address these chal-
lenges while summarizing the existing body of literature to
establish the current state of the evidence and to identify
remaining gaps. We will publish our findings with the goal
of helping to inform potential research directions and
changes in post-market surveillance in the future.
Additional files
Additional file 1: PRISMA-P Checklist. (DOC 71 kb)
Additional file 2: Medline Search Strategy. (DOC 32 kb)
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